🧬 CMPX $1.5M Premium Collection Ahead of Binary Data — Someone Is Selling Calls Before COMPANION-002 Results!

📅 April 14, 2026 | 🔥 Unusual Activity Detected

---

🎯 The Quick Take

A single trader just sold $1.5M in CMPX calls at the $6 strike expiring May 2026 — collecting premium income right before what could be one of the most important catalysts in Compass Therapeutics' history. With COMPANION-002 Phase 3 PFS and OS data expected in April 2026 — literally any day now — this $1.5M premium sale is a bold income bet that the binary data event does NOT send the stock above $6 by May 15. High stakes, tight window.

---

📊 Company Overview

Compass Therapeutics (CMPX) is a clinical-stage oncology biotech developing bispecific antibody therapies targeting solid tumors and hematologic cancers:

• Market Cap: ~$931M (as noted in user brief; catalyst report shows ~$350M — reflecting recent stock moves)
• Exchange: NASDAQ
• Industry: Pharmaceutical Preparations / Clinical-Stage Oncology
• Current Price: $5.17-$5.35
• Cash: $209M (runway into 2028)
• Stage: Clinical (no revenue, $66.5M net loss in 2025)
• Lead Program: Tovecimig (CTX-009) — DLL4/VEGF-A bispecific antibody in biliary tract cancer
• Pipeline: CTX-8371 (PD-1/PD-L1), CTX-471 (CD137 agonist), CTX-10726 (PD-1/VEGF-A)

Compass is a classic clinical-stage biotech bet: strong analyst consensus (Strong Buy, 16 of 17 analysts rate Buy), $12-$14 average price targets implying 124-170% upside, and a near-term binary data catalyst that could be a stock-defining moment.

---

💰 The Option Flow Breakdown

The Tape (April 14, 2026 @ 10:20:41):

🤓 What This Actually Means

This is a sell-to-open (STO) — someone sold these calls, collecting $1.5M upfront. Here is the full picture:

• 💰 Premium collected: $1.50 per share × 100 × 9,994 contracts = $1.499M cash in hand today
• 📏 How OTM: The $6 strike is 16.1% above the current spot of $5.17. That is a meaningful gap to cover in 31 days.
• 📅 Expiration: May 15, 2026 — 31 days away
• 📊 Volume vs OI: 9,994 contracts against 1,200 OI — 8.3x OI, fresh position, significant conviction
• 💵 Option price: $1.50 per contract on a $5.17 stock is 29% of the stock price in premium — extremely high implied volatility, reflecting how uncertain the market is about the upcoming binary data event

What is the seller's thesis? The $6 call seller is making a specific bet: CMPX will NOT trade above $6 by May 15. They are collecting $1.50/share — but they are exposed to unlimited upside if the stock explodes on positive COMPANION-002 data.

This could be:

1. Covered call writer: Someone holding ~1 million shares of CMPX collecting income ahead of the readout, comfortable selling their upside above $6
2. Premium seller: A sophisticated trader who believes the market is overpricing the options given the trial's modest primary endpoint result (17.1% ORR vs. 5.3% control), and is betting OS data will be inconclusive or muted

The risk: If COMPANION-002 shows statistically significant OS benefit — a genuine cure for a disease with no good options — CMPX could gap to $10, $12, or higher. The call seller would need to deliver shares at $6 while the stock trades much higher. That is the nightmare scenario for this trade.

Unusual score context: 9,994 contracts vs. 1,200 OI — roughly 8.3x average outstanding interest. For a small-cap biotech like CMPX, this is a standout volume print that does not happen more than a few times a year.

---

📈 Technical Setup / Chart Check-Up

YTD Performance Chart

CMPX has been in a consolidation pattern, currently trading around $5.17-$5.35. The stock is a classic clinical-stage biotech — relatively quiet on most days, with the real action coming from clinical data prints. The January 2026 Phase 2/3 COMPANION-002 primary endpoint already beat (17.1% ORR vs. 5.3%), so the market has partially priced in the oncology thesis. But OS data is the bigger prize — and the market is waiting.

Key observations:

• 📊 Tight range: Trading between $5.14-$5.35 day-range, digesting the Q1 2026 80% OS event threshold news
• 🧬 Binary setup: The daily candles tell you nothing — everything hinges on the upcoming data
• 📈 Strong analyst coverage: Strong Buy consensus, $12-$14 average target — the fundamental story has institutional support
• 💸 High IV: A $1.50 option on a $5.17 stock (29% of spot) confirms the options market is pricing a massive potential move

Gamma-Based Support & Resistance Analysis

Current Price: $5.35

The gamma structure here is very sparse compared to large-cap names — typical for a small-cap biotech — but what does exist is highly informative:

🔵 Support Level:

• $5.00 — The only meaningful support level at 0.159B total gamma. Put gamma slightly dominates here (0.103B put vs 0.056B call), creating some dealer buy pressure on dips to $5.00.

🟠 Resistance Level:

• $6.00 — THE critical level. 1.981B total gamma, overwhelmingly call-heavy (1.969B call vs 0.012B put). This is massive call concentration at exactly the sold strike. Market makers are delta-hedging here — this level acts like a magnet and a ceiling simultaneously.

What this means for traders: The gamma map on CMPX tells a simple story: $5.00 is a floor, $6.00 is the wall. The call seller chose the EXACT level where gamma concentration creates maximum friction for the stock — it is the largest and only significant resistance in the entire GEX structure. This is not random; the trader understands gamma dynamics.

Net GEX Bias: Bullish (4.22B call gamma vs 0.32B put gamma) — call gamma dramatically dominates, but the $6.00 gamma wall will be the proving ground if the stock runs on positive data.

Implied Move Analysis

Options market pricing:

• 📅 This Week (April 17 — 3 days): ±$1.38 (±25.85%) → Range: $3.96 - $6.72

That is not a typo. The weekly implied move for CMPX is 26% — pricing in a potential move to $6.72 on the upside or $3.96 on the downside within the next three days. This directly reflects the imminent COMPANION-002 data readout. The options market is essentially saying: "We have no idea where this stock is going, and it depends entirely on trial results."

Translation: When a biotech has a 26% weekly implied move, it means there is a live binary event priced in right now. The $1.50 in premium collected by the call seller reflects this extreme uncertainty — they are being paid handsomely for taking on that binary risk.

Note: Only weekly/monthly OPEX data is available for CMPX, reflecting limited long-dated options liquidity for a small-cap biotech. The absence of quarterly or yearly implied move data is typical for names in this category.

---

🎪 Catalysts

🔥 CRITICAL — COMPANION-002 PFS and OS Data (April 2026 — ANY DAY NOW!)

This is the entire thesis in one readout. The prespecified 80% OS event threshold was reached in Q1 2026, triggering the final analysis. Data is expected in April 2026 — potentially within the next few days.

What investors need to know:

• Primary endpoint (already hit in April 2025): ORR of 17.1% for tovecimig + paclitaxel vs. 5.3% for paclitaxel alone (p=0.031) in second-line biliary tract cancer
• What we are waiting for: Whether that ORR advantage translates to statistically significant PFS and/or OS improvements
• Trial size: 168 patients, randomized 2:1 — small by pivotal trial standards, which limits statistical power
• If OS is positive: Path to NDA filing, potential partnership discussions, and the stock could re-rate significantly higher toward analyst targets of $12-$14
• If OS is negative or inconclusive: The stock could sell off 30-50%, dropping back toward $3-$4 range

The 26% weekly implied move tells you exactly how the market is weighing this binary event.

🚀 Pipeline Catalysts (2026)

CTX-8371 Expansion Cohort Data — 2026

The PD-1 x PD-L1 bispecific already showed striking early responses: a patient with NSCLC achieved 100% reduction in target lesion tumor burden, and a TNBC patient showed >90% reduction durable through week 32. Expansion cohorts in TNBC and NSCLC (n=28 each) are open and enrolling. Data from these cohorts during 2026 would be the next major catalyst after COMPANION-002.

CTX-10726 Phase 1 Initiation — Q1-Q2 2026

CTX-10726, a PD-1 x VEGF-A bispecific antibody, is entering Phase 1. First-in-human data will diversify Compass beyond the tovecimig program.

CTX-471 Phase 2 Initiation — H1 2026

A Phase 2 of the CD137 agonist in NCAM-expressing tumors is expected in H1 2026, following Phase 1 responses correlated with NCAM expression.

Potential Partnership Deals

According to Seeking Alpha's analysis, positive COMPANION-002 OS data could catalyze partnership discussions for tovecimig in the commercialization phase. Biliary tract cancer is an underserved market, making an approved bispecific an attractive licensing asset.

📊 Recent Company Milestones

2025 Full-Year Results (March 5, 2026)

Compass reported 2025 results: $66.5M net loss, R&D up 32% YoY driven by tovecimig and CTX-10726 manufacturing scale-up, and $209M in cash secured after a $129M public offering. The company is funded into 2028 — no near-term dilution risk.

---

🎲 Price Targets & Probabilities

🐂 Bull Case — $10-$15+ (if COMPANION-002 OS is positive) 16 of 17 analysts rate CMPX a Buy with average targets of $12-$14. Positive OS data supporting an NDA filing would be a transformational event — the stock could re-rate toward those analyst targets. The $6 gamma wall ($6.72 weekly implied upper range) would be the first test; above that, $8-$10 is the next major zone. In this scenario, the call seller faces significant losses on their short calls.

📊 Base Case — $4.50-$6.00 (data in line, muted reaction) If OS trends positive but does not reach traditional statistical significance thresholds (p < 0.05), the market might react modestly — a 10-20% move either way. The $6 gamma wall holds, the sold calls expire worthless or near-worthless, and the call seller collects most or all of the $1.5M premium.

🐻 Bear Case — $2.50-$4.00 (if OS data disappoints) A small trial of 168 patients with a modest primary ORR benefit may not translate to statistically significant OS data. If negative, expect a 30-50% drawdown. The $5.00 gamma support is the first floor; below that, $3-$4 is the next technical support. In this scenario, the short calls expire worthless and the seller keeps all $1.5M — but their underlying stock position (if covered call) takes a big hit.

---

💡 Trading Ideas

🛡️ Conservative — "Wait for the Binary Event to Resolve"

Do not trade CMPX until after the COMPANION-002 data prints

• Seriously — the 26% weekly implied move tells you this stock is going to make a significant move, and you do not know which direction
• Once data is out, evaluate: positive data = consider buying the dip on any pullback toward $7-$8 as the stock consolidates post-spike; negative data = avoid for at least 2-4 weeks until the dust settles
• Why this works: Letting the binary event resolve removes your biggest risk. You miss the immediate spike but participate in the sustained move with much more certainty.

⚖️ Balanced — "The Strangle Play on Binary Data"

Buy CMPX $4 Put + Buy $7 Call, April 17 expiration (capturing the data event)

• Both options are pricing in the move; a strangle profits if the stock moves more than the combined premium in either direction
• Approximate cost: ~$1.80-$2.50 total (both legs combined)
• You profit if CMPX moves more than ~35% either way by April 17
• Why this works: You do not need to guess the direction — just that the data creates a big move. The 26% implied move suggests the market expects it. This is a volatility bet, not a directional bet.

🚀 Aggressive — "The Long Call Lottery Ahead of the Readout"

Buy CMPX $7 or $8 Call, May 15 expiration

• Approximate cost: $0.50-$0.80 per contract
• Need: Positive COMPANION-002 OS data to send the stock above $7-$8
• Risk: Full premium loss if data is negative or inconclusive
• Potential payoff: 3-5x if the stock re-rates toward $10-$12 analyst targets
• Why this works: You define your maximum loss while capturing the tail-end upside of a biotech binary. This is a speculative bet — size accordingly (small position sizing only).

---

⚠️ Risk Factors

• 🧬 Binary data risk (COMPANION-002 is imminent): The April OS readout can send this stock to $10+ or back to $3. There is no middle ground on a Phase 3 OS endpoint in oncology. The trial enrolled only 168 patients, limiting statistical power for OS.
• 📉 Call seller's exposure: The trader who sold $1.5M in calls is exposed to theoretically unlimited upside if CMPX gaps up 50%+ on positive data. Their $1.50 premium collected would not come close to covering $5-$8 in ITM call exposure if the stock goes to $10-$12.
• 💸 Clinical-stage burn rate: $66.5M annual net loss with no revenue. Despite $209M in cash, accelerating clinical programs could push dilution risk forward if COMPANION-002 disappoints and a capital raise is needed.
• ⚖️ Regulatory path: Even with positive Phase 3 OS data, FDA approval in biliary tract cancer could require a confirmatory trial, delaying commercialization by 2-3 years and requiring additional capital.
• 🔬 Competition: Other developers targeting BTC with different mechanisms, plus the broader immuno-oncology crowding, could limit market exclusivity if tovecimig reaches approval.
• 🔀 Dilution history: The 2025 offering raised $129M but diluted shareholders. Future rounds remain possible.

---

🎯 The Bottom Line

Real talk: The most interesting thing about this trade is not the premium collected — it is the TIMING. Selling $1.5M in covered calls at $6 strike when Phase 3 OS data is due literally any day this week is either incredibly courageous or very well-informed about what the data will show.

The call seller is making $1.50/share on a $5.17 stock (29% of spot in premium) because the options market is pricing in the possibility of a massive binary move. They believe that $1.50 more than compensates for the risk — and if they own the stock as a covered call, they are comfortable exiting at an effective price of $7.50 ($6 strike + $1.50 premium) if the data is spectacular.

If you are bullish on the COMPANION-002 data: Do NOT sell calls right now — let the data speak. If positive, the stock will blow through $6, $7, $8 and the short call position would be painful. Instead, consider a small long call position or wait for the data to print.

If you are neutral/bearish on the binary: Selling premium ahead of binary events can work, but you need to size extremely carefully. A 30-50% downside on a bad readout hurts the stock; a 50-100% upside on a positive readout hurts the short call. Neither is comfortable.

If you are just watching: Mark April/May 2026 as the period where CMPX either breaks out toward analyst targets of $12-$14 or retreats to $3-$4. The binary outcome will define this stock's trajectory for 2026-2027.

One key date: May 15, 2026 — option expiration. But the real action happens whenever Compass Therapeutics issues a press release announcing the COMPANION-002 OS data. Watch for that announcement closely.

---

⚠️ Options trading involving clinical-stage biotechs carries extreme risk due to binary data events. Options can expire worthless, and selling options without owning the underlying stock creates theoretically unlimited loss potential. Clinical trial outcomes are inherently uncertain and past data results do not guarantee future statistical success. This analysis is for informational purposes only and does not constitute financial advice. Always do your own research before trading.